SCHEDULE 13G: JPMorgan Chase & Co. Discloses 5.1% Stake in Bristol-Myers Squibb

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 5.1% in Bristol-Myers Squibb Company as of March 31, 2025.

Summary

• JPMorgan Chase & Co. reported beneficial ownership of 104,688,497 shares of Bristol-Myers Squibb Company's common stock.
• This ownership represents 5.1% of Bristol-Myers Squibb's outstanding common stock.
• The filing was made under Rule 13d-1(b), indicating that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• JPMorgan Chase & Co. holds sole voting power over 87,166,682 shares and shared voting power over 570,532 shares.
• The institution also holds sole dispositive power over 103,787,007 shares and shared dispositive power over 860,108 shares.
• Several subsidiaries of JPMorgan Chase & Co. are identified as entities through which the securities are held, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, and various JPMorgan Asset Management entities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a 13G is a factual disclosure, a significant stake by a reputable financial institution like JPMorgan Chase & Co. can be viewed as a positive signal of confidence in the issuer, Bristol-Myers Squibb. The 'ordinary course of business' and 'not for control' statements also indicate a stable, passive investment.

Positives

• The disclosure of a significant 5.1% stake by a major financial institution like JPMorgan Chase & Co. can be interpreted as a vote of confidence in Bristol-Myers Squibb's long-term prospects and stability.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist intent, which can provide stability to the issuer's stock.

Negatives

• The document itself does not contain any negative information regarding Bristol-Myers Squibb's performance or outlook.

Risks

• The document does not detail specific risks related to Bristol-Myers Squibb Company. It is a disclosure of ownership by a third party.

Future Outlook

The document is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Bristol-Myers Squibb's future performance or JPMorgan Chase & Co.'s future investment intentions beyond the scope of the filing's purpose.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Rachel Tsvaygoft, Vice President of JPMorgan Chase & Co.)

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major financial institution in a leading pharmaceutical company. Such disclosures are common for large asset managers and banks that hold substantial stakes in publicly traded companies for their clients or through various investment vehicles. It reflects ongoing institutional interest in the healthcare and pharmaceutical sectors, which are often viewed as defensive investments or growth opportunities depending on market conditions and drug pipelines.

Comparison to Industry Standards

• This filing is a standard disclosure for institutional investors crossing the 5% beneficial ownership threshold in a public company, as mandated by SEC regulations.
• The 5.1% stake held by JPMorgan Chase & Co. in Bristol-Myers Squibb is a substantial position, comparable to significant institutional holdings seen in other large-cap pharmaceutical companies like Pfizer, Merck, or Johnson & Johnson by major asset managers such as BlackRock, Vanguard, or State Street, which routinely hold passive stakes for diversified portfolios.

Stakeholder Impact

• **Shareholders**: The disclosure provides transparency regarding a significant institutional holder, which can influence investor perception and potentially provide a sense of stability due to a large, passive institutional investment.
• **Company Management**: Awareness of a major institutional shareholder, though passive, can be a factor in strategic considerations, although the filing explicitly states no intent to influence control.

Next Steps

• JPMorgan Chase & Co. will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership (e.g., an increase or decrease of 1% or more) or if their intent changes from passive to active.

Key Dates

Keywords

Bristol-Myers Squibb, JPMorgan Chase & Co., SEC Filing, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Pharmaceuticals, Healthcare, Investment